ETON --3x FDA Decisions: July & October 2019 , May 2020 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ETON --3x FDA Decisions: July & October 2019 , May 2020

ETON 18.20

-0.4%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

From: BioHero	6/25/2019 9:24:46 AM
	of 16

The Deals closed just since the start of the year ... Bausch Health acquires U.S. rights for Eton's eye drop ..2019-02-19 stockwatch.com Eton Pharmaceuticals Announces Licensing of Lamotrigine New Drug Application and Provides Pipeline Update ir.etonpharma.com Unique patent-pending formulation of lamotrigine addresses significant unmet need in pediatric epilepsy patients NDA was submitted in May 2019; product launch anticipated in 1H 2020 Lamotrigine market currently exceeds $700 million annually Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates ir.etonpharma.com Eton Pharmaceuticals Announces Licensing of Oral Liquid Product Candidate ET-104 ir.etonpharma.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext